Dose reductions and interruptions
| Mean daily dose . | No. of patients . | |||
|---|---|---|---|---|
| Overall . | 1st quarter . | 2nd quarter . | 2nd half . | |
| 600-800 mg, n (%) | 54 (74) | 60 (82) | 55 (75) | 51 (71) |
| 400-599 mg, n (%) | 13 (18) | 8 (11) | 14 (19) | 15 (21) |
| Less than 400 mg, n (%) | 6 (8) | 5 (7) | 4 (5) | 6 (8) |
| Patients with dose interruption, n (%) | 38 (52) | 27 (37) | 18 (25) | 16 (22) |
| No. of interruptions | 86 | 41 | 25 | 27 |
| Median cumulative duration of interruptions, days (range) | 19 (3-169) | 13 (1-48) | 12 (5-48) | 20 (5-99) |
| Mean daily dose . | No. of patients . | |||
|---|---|---|---|---|
| Overall . | 1st quarter . | 2nd quarter . | 2nd half . | |
| 600-800 mg, n (%) | 54 (74) | 60 (82) | 55 (75) | 51 (71) |
| 400-599 mg, n (%) | 13 (18) | 8 (11) | 14 (19) | 15 (21) |
| Less than 400 mg, n (%) | 6 (8) | 5 (7) | 4 (5) | 6 (8) |
| Patients with dose interruption, n (%) | 38 (52) | 27 (37) | 18 (25) | 16 (22) |
| No. of interruptions | 86 | 41 | 25 | 27 |
| Median cumulative duration of interruptions, days (range) | 19 (3-169) | 13 (1-48) | 12 (5-48) | 20 (5-99) |
The percentage of patients who received a different cumulative median daily dose of nilotinib in the first quarter, in the second quarter, in the second half, and overall is shown. At 12 months, the number of patients receiving the full dose of 800 mg daily was 51 (71%), the number of patients with a permanent dose reduction to 400 mg was 18 (25%), and the number of patients receiving less than 400 mg was 3 (4%).